- The share
- Press releases
- Financial calendar
- Financial reports
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- CODE OF CONDUCT
- Thank you
XVIVO’s patents for the heart preservation fluid approved in the US and Europe
XVIVO has two main patents in the field of heart transplantation. The first of these covers the preservation fluid that is used in heart preservation and the other covers important parts of the evaluation equipment that is to be used for heart evaluation after preservation, but before transplantation. Patent applications have been submitted from both of these patent families recently.
These patents strengthens XVIVO´s position in the field of heart transplantation. Patents are important in XVIVO’s research-intensive business areas and not only entail a temporary monopoly situation for XVIVO’s products, but can also be important in discussions with potential collaboration partners and to give XVIVO freedom in its further research and product development.
“It is positive that these patents have been approved on important markets in the world. This means that the company will continue to invest in products for both preservation and evaluation of the heart with even greater confidence,” says Magnus Nilsson, CEO of XVIVO Perfusion.
May 2, 2019
XVIVO Perfusion AB (publ)
Magnus Nilsson, CEO
For further information please contact:
Christoffer Rosenblad, CFO, +46 735 192159, firstname.lastname@example.org
Magnus Nilsson, CEO, +46 31 788 2150, email@example.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 am CET on May 2, 2019.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.